coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antoni Ribas(University of California, Los Angeles), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Michele Maio(University of Siena), Grant A. McArthur(The University of Melbourne), Ilsung Chang, Stephen P. Hack, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Daniil Stroyakovskiy(Shikoku Cancer Center), James Larkin(Trinity College Dublin), L. Thomas(University of Liverpool), Claus Garbe(University of Tübingen), Victoria Atkinson(Greenslopes Private Hospital), Brigitte Dréno(Nantes Université)
Cited by 31
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k